Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ARS Pharmaceuticals (SPRY)
NASDAQ:SPRY
RESEARCH TOOLSreports
Holding SPRY?
Track your performance easily
Earnings Data
Report Date
Mar 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.13Last Year’s EPS
-0.07Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 13, 2021
|% Change Since: -24.32%
|Next Earnings Date:Mar 29, 2021
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including the successful approval and initial launch of Neffy, a strategic partnership with ALK, and a strong financial position. While there were minor challenges with inventory stocking and cash price redemption, the overall sentiment is positive due to the strong early sales and enthusiastic reception by healthcare providers and patients.Company Guidance
During the ARS Pharmaceuticals Third Quarter 2024 earnings call, significant guidance was provided regarding the commercialization efforts and financial outlook for neffy, the company's needle-free epinephrine product. The product, approved in the U.S. and Europe, has seen encouraging early adoption, with shipments starting on September 23, 2024, and broader retail availability from early October. The initial U.S. sales and marketing efforts have engaged over 5,700 healthcare providers, with 1,700 physicians submitting prescriptions through the neffyconnect program. Financial highlights include a total revenue of $2.1 million for Q3 2024, with $0.6 million from neffy sales and $1.5 million from collaboration revenue. The company reported a GAAP net loss of $19.1 million, ending the quarter with $204.6 million in cash. Additionally, a $145 million upfront payment from a licensing agreement with ALK significantly bolstered their cash position to $349.6 million on a pro forma basis, supporting their operational plans for at least the next three years. The company aims for 60% commercial coverage within six months of launch, targeting 80% within a year, while prioritizing patient access and affordability.Approval and Launch of Neffy
Neffy 2 mg, the first needle-free epinephrine product, was approved in the US and Europe for allergic reactions. The US launch began with shipments available from retail pharmacies and strong support from the medical community.
Strategic Licensing Agreement with ALK
A strategic licensing agreement was signed with ALK for marketing rights in Europe, Canada, and other regions, resulting in a $145 million upfront payment, boosting ARS's cash position to $350 million.
Initial Sales and Positive Feedback
Neffy recorded $0.6 million in net product revenue from just 1 week of sales. Positive feedback from healthcare providers and patients, with 1,700 prescriptions submitted through NeffyConnect.
Strong Financial Position
Ending the third quarter with $204.6 million in cash and pro forma cash of $349.6 million, supporting operating plans for at least 3 years.
---
SPRY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SPRY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $16.61 | $14.08 | -15.23% |
| Aug 06, 2024 | $9.78 | $9.56 | -2.25% |
| May 09, 2024 | $8.80 | $8.74 | -0.68% |
| Mar 21, 2024 | $9.00 | $8.65 | -3.89% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does ARS Pharmaceuticals (SPRY) report earnings?
ARS Pharmaceuticals (SPRY) is schdueled to report earning on Mar 20, 2025, TBA Not Confirmed.
What is ARS Pharmaceuticals (SPRY) earnings time?
ARS Pharmaceuticals (SPRY) earnings time is at Mar 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SPRY EPS forecast?
SPRY EPS forecast for the fiscal quarter 2024 (Q4) is -0.13.
---